Drug details

Tecartus (brexucabtagene autoleucel suspension)

type of CAR-T Cell Therapies

Tecartus (brexucabtagene autoleucel) is a CD19-directed genetically modified autologous T cell immunotherapy used to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL).

This drug may have the following side effects:

• nausea,
• rash,
• diarrhea,
• fever,
• shortness of breath,
• chills,
• constipation,
• musculoskeletal pain,
• headache,
• low blood pressure (hypotension),
• fatigue,
• cough,
• irregular heartbeats,
• insomnia,
• tremor,
• fast heart rate,
• infection,
• decreased appetite,
• cytokine release syndrome,
• fluid retention (edema),
• encephalopathy,
• low blood oxygen (hypoxia),
• motor dysfunction,
• fluid around the lungs (pleural effusion), and
• problems speaking and understanding language (aphasia)

The following drugs are related to Tecartus, either as a replacement or used together:

• Calquence (acalabrutinib capsules)
• Brukinsa (zanubrutinib capsules)
• Imbruvica (ibrutinib capsules)
• Riabni (rituximab-arrx injection)